To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
810
Stephen M. Auerbach, MD
Newport Beach, California, United States
Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment
Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12
Time frame: 12 weeks
Percent of Participants With Equal of Greater Than 50% Reduction in Mean Nocturic Episodes
Percent of participants with equal of greater than 50% reduction in mean nocturic episodes over the twelve week period
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.